- Home
- SER vs HOWL Comparison
SER vs HOWL Comparison
Compare SER & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- HOWL
- Stock Information
- Founded
- SER 2017
- HOWL 2017
- Country
- SER United States
- HOWL United States
- Employees
- SER N/A
- HOWL N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- HOWL Health Care
- Exchange
- SER Nasdaq
- HOWL Nasdaq
- Market Cap
- SER 56.5M
- HOWL 50.3M
- IPO Year
- SER 2018
- HOWL 2021
- Fundamental
- Price
- SER $5.75
- HOWL $1.36
- Analyst Decision
- SER Strong Buy
- HOWL Strong Buy
- Analyst Count
- SER 1
- HOWL 3
- Target Price
- SER $11.00
- HOWL $8.33
- AVG Volume (30 Days)
- SER 10.4K
- HOWL 661.2K
- Earning Date
- SER 05-08-2025
- HOWL 05-08-2025
- Dividend Yield
- SER N/A
- HOWL N/A
- EPS Growth
- SER N/A
- HOWL N/A
- EPS
- SER N/A
- HOWL N/A
- Revenue
- SER $51,000.00
- HOWL $1,143,000.00
- Revenue This Year
- SER N/A
- HOWL N/A
- Revenue Next Year
- SER N/A
- HOWL $900.00
- P/E Ratio
- SER N/A
- HOWL N/A
- Revenue Growth
- SER N/A
- HOWL N/A
- 52 Week Low
- SER $3.81
- HOWL $0.60
- 52 Week High
- SER $14.57
- HOWL $4.73
- Technical
- Relative Strength Index (RSI)
- SER 54.81
- HOWL 69.86
- Support Level
- SER $5.01
- HOWL $1.14
- Resistance Level
- SER $6.00
- HOWL $1.31
- Average True Range (ATR)
- SER 0.32
- HOWL 0.11
- MACD
- SER 0.01
- HOWL 0.02
- Stochastic Oscillator
- SER 81.65
- HOWL 93.02
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.